Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.
about
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteBroad neutralization coverage of HIV by multiple highly potent antibodiesGeneration of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaquesBoosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyHIV-1 autologous antibody neutralization associates with mother to child transmissionAn augmented probit model for missing predictable covariates in quantal bioassay with small sample size.Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccinesHighly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model.Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoproteinAdeno-associated virus delivery of broadly neutralizing antibodiesHIV-1 vaccine immunogen design strategies.Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges.
P2860
Q27319450-3BE43C5E-4ADE-4862-B128-286C8B4E2E5BQ29615361-32EF379F-AC9B-408F-BAD1-32636E0B7257Q33826773-C9C8E895-67A2-41BE-BA20-5332B8A799F0Q33955745-12E2A432-78A3-4E3C-9899-8142056E52CAQ34120088-DA18C240-B306-4BD1-9EE1-398E81E3C363Q34204047-FBFC5569-649C-4638-968E-B8168C0E1BECQ34230556-DD4AD46C-5A79-4380-A58F-C061A0F46A48Q34630446-759D2F75-987F-459C-AB5D-E0EABF8392C9Q34853667-D8317742-0484-43EB-997B-39A0549D5CD4Q35050542-785BEB2C-E147-429C-BDED-D634EF804011Q35274968-541732CB-2085-4CCD-805B-3E497133E6A1Q36356350-701B458E-91EB-4FE0-8516-51D8FB7FA6AFQ36414891-BE6889DE-30BC-43A4-9A4A-5CC6FB475DF6Q36438523-99B48D11-5112-4FB4-B54D-DCB94BEA5C17Q36742228-D8CBDEC8-AFB8-43C8-84E5-A4059796EF0AQ37025857-C7605CCC-4D60-4048-A542-491B564B10AAQ37036786-586FC3DF-E811-428C-9560-9E5B169D3A28Q37036833-906B64DC-1BB1-4003-B187-75D25753B8DBQ38196689-DEF49E3A-1C74-42F2-AE05-63272E4179CCQ38330424-A436BD15-8651-433E-8867-9E4998C4CB11Q38541824-83023461-5C17-4D62-8A77-861A1F6AB959Q38936872-CD38B374-C789-442D-8271-3DC73C3A068CQ42204816-5D50C661-3EEB-409E-AA56-85D881DC8160Q51743315-53AD2A2A-4B3F-40F2-8AFC-B8D618F16DED
P2860
Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Neutralizing antibody titers c ...... llenge using the TZM-bl assay.
@ast
Neutralizing antibody titers c ...... llenge using the TZM-bl assay.
@en
type
label
Neutralizing antibody titers c ...... llenge using the TZM-bl assay.
@ast
Neutralizing antibody titers c ...... llenge using the TZM-bl assay.
@en
altLabel
Neutralizing antibody titers c ...... allenge using the TZM-bl assay
@en
prefLabel
Neutralizing antibody titers c ...... llenge using the TZM-bl assay.
@ast
Neutralizing antibody titers c ...... llenge using the TZM-bl assay.
@en
P2093
P2860
P921
P356
P1476
Neutralizing antibody titers c ...... llenge using the TZM-bl assay.
@en
P2093
Dean A Follmann
Malcolm A Martin
Martha C Nason
Ronald Willey
Yoshiaki Nishimura
P2860
P356
10.1089/AID.2009.0144
P407
P577
2010-01-01T00:00:00Z